B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL.
- BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL.
- The new Daytona Beach facility is part of B. Braun's commitment to invest over $1 billion dollars to alleviate IV fluid shortages by creating additional supply and manufacturing capacity in the United States.
- "FDA approval of our state-of-the-art pharmaceutical manufacturing plant in Daytona Beach is a win for patients across the United States," said Jean-Claude Dubacher, Chairman and CEO of B. Braun of America.
- B. Braun Medical is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculapand CAPS.